healthcare · stock-sale · committee-conflict
Sen. John Boozman Trims Johnson & Johnson Stake Amid Healthcare Committee Roles
The Arkansas Republican sold up to $15,000 of JNJ stock as part of a broader, adviser-style portfolio rebalancing.
2026-09-23 — John Boozman · JNJ
Key facts
- Sen. John Boozman (R-AR) sold between $1,001 and $15,000 of Johnson & Johnson (JNJ) stock on August 20, 2026.
- Boozman serves on the Senate Committee on Veterans' Affairs and the Senate Appropriations Subcommittee on Labor, HHS, and Education.
- The sale was executed alongside four other trades, including purchases of diversified equity ETFs, suggesting routine portfolio rebalancing.
- The trade occurred shortly after JNJ announced a proposed talc litigation settlement and executive leadership changes.
Sen. John Boozman (R-AR) executed a partial sale of his holdings in healthcare giant Johnson & Johnson on August 20, 2026. The transaction, valued between $1,001 and $15,000, was disclosed in a financial filing on September 11, 2026, representing a 22-day disclosure lag.
Boozman has legislative exposure to healthcare policy through his seat on the Senate Committee on Veterans' Affairs, which oversees veterans' health systems, and the Senate Appropriations Subcommittee on Labor, Health and Human Services, and Education, which funds public health agencies. He also serves as Chair of the Senate Committee on Agriculture, Nutrition, and Forestry. While these committee assignments touch the healthcare sector, our analysis scored the trade 22/100, indicating a low likelihood of an informational signal.
The transaction was not an isolated stock pick. On the same day and adjacent days, Boozman executed four other trades, including purchasing shares in three diversified equity ETFs (AVUV, IJR, and SPYM) and fully selling his stake in the WWSYX mutual fund, which was valued between $15,001 and $50,000. This multi-asset block is highly characteristic of programmatic portfolio rebalancing managed by an external financial adviser.
Members of Congress are required by the STOCK Act to disclose trades within 45 days, and disclosed amounts are reported in ranges.
Boozman’s trade also followed several major, widely publicized corporate developments at Johnson & Johnson. The company announced a proposed $6.48 billion resolution of ovarian talc litigation on July 27, 2026, and disclosed key executive leadership changes on August 4, 2026. Corporate insiders at the company were also net sellers during this period; Executive Vice President Jennifer Taubert sold 15,000 shares on August 17, just three days before Boozman’s transaction.
For Boozman, the prescription for his portfolio appears to be passive index funds over individual healthcare stocks.
Sources
- Johnson & Johnson Form 8-K (July 27, 2026) — SEC EDGAR
- Johnson & Johnson Form 8-K (August 4, 2026) — SEC EDGAR